<DOC>
	<DOCNO>NCT00625456</DOCNO>
	<brief_summary>This Phase I , open-label , dose-escalation trial patient advanced/metastatic solid tumor refractory standard therapy ; tumor may include malignant melanoma , non-small cell lung cancer , renal cell carcinoma , squamous cell carcinoma head neck . These tumor type select evidence biological activity observe tumor type Phase I study JX-594 ( Pexa-Vec ) administer intratumoral injection patient metastatic disease liver . Patients receive treatment one five dose level sequential dose-escalating design .</brief_summary>
	<brief_title>Safety Study Recombinant Vaccinia Virus Treat Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<criteria>Histologicallyconfirmed , advanced/metastatic solid tumor refractory standard therapy patient refuse tolerate standard therapy ; tumor may include malignant melanoma , nonsmall cell lung cancer , renal cell carcinoma , squamous cell carcinoma head neck At least one measurable tumor mass CT/MRI ( i.e . lesion accurately measure least one dimension long diameter &gt; 1 cm ) At least one tumor mass amenable biopsy and/or FNA Expected survival approximately 16 week longer Karnofsky Performance Score ( KPS ) ≥ 70 Age ≥18 year WBC ≥ 3,500 cells/mm3 ≤ 50,000 cells/mm3 ANC ≥ 1,500 cells/mm3 Hemoglobin ≥ 10 g/dL Platelet count ≥ 100,000 plts/mm3 Total bilirubin ≤ 1.5 x ULN AST , ALT ≤ 2.5 x ULN Serum chemistry within normal limit ( WNL ) Grade 1 If patient diabetic screen random glucose &gt; 160 mg/dL , fast glucose must do patient must WNL Grade 1 order eligible study . Acceptable coagulation status : INR ≤ ( ULN + 10 % ) CD4 count ≥ 500/mm3 Significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . systemic corticosteroid ) Known myeloproliferative disorder require systemic therapy History exfoliative skin condition ( e.g . eczema ectopic dermatitis ) require systemic therapy Tumor ( ) invade major vascular structure ( e.g . carotid artery ) Tumor ( ) location would potentially result significant clinical adverse effect posttreatment tumor swell occur ( e.g . tumor impinge upper airway affect biliary tract drainage , etc . ) Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion Severe unstable cardiac disease Current , know CNS malignancy ( history completely resect irradiated brain metastasis allow ) Received anticancer therapy within 4 week prior first treatment ( 6 week case mitomycin C nitrosoureas ) Use antiviral , antiplatelet , anticoagulation medication [ Patients discontinue medication within 7 day prior first treatment may eligible study . ] Pulse oximetry O2 saturation &lt; 90 % rest Experienced severe systemic reaction sideeffect result previous smallpox vaccination Household contact exclusion : Women pregnant nursing infant Children &lt; 5 year old History exfoliative skin condition ( e.g . eczema ) stage require systemic therapy Significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . systemic corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>phase I</keyword>
	<keyword>advanced metastatic solid tumor</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>vaccinia virus</keyword>
	<keyword>melanoma</keyword>
	<keyword>lung cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>